Ami Organics Limited, a leading global manufacturer of advanced pharmaceutical intermediates and speciality chemicals, has signed another definitive agreement with Fermion, a fully owned subsidiary of Orion Corporation, Finland.

As part of the agreement, Ami Organics will manufacture couple of additional advanced pharmaceutical intermediates for Fermion.

The two additional advanced pharmaceutical intermediates signed will be used in captive consumption for the manufacture of earlier advanced pharmaceutical intermediates signed with Fermion. This agreement will lead to value addition to the final advanced intermediates which will be supplied by Ami Organics to Fermion, leading to higher value of end product. This will also help company become leading supplier of Fermion, supplying key advanced intermediates.

The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25.

Ami Organics has already signed two agreements with Fermion in November 2022 and September 2023 for supply of two advanced pharmaceutical intermediates. This agreement is in addition to the previous agreements and further increases the total value of the CDMO contract with Fermion.

Commenting on development, Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: "I am happy to inform you that we continue to strengthen our relationship with our esteem customer - Fermion, with signing of two more advanced pharmaceutical intermediates. The new agreement marks a significant stride forward in our collaboration with Fermion showcasing our dedication for delivering more value-added products to our customers and the trust reposed on our capabilities."